

## Sisram Medical’s associate company Tianjin JuveStar released Phase IIb result of lipolysis injection, reduction of submental fat by 15% through one treatment

Hong Kong, June 28, 2022 -- Sisram Medical Ltd (the “**Company**” or “**Sisram Medical**”, stock code: 1696.HK; together with its subsidiaries referred as the “**Group**”), is glad to share that the phase IIb clinical result of JS-001 by its associate company Tianjin JuveStar Biotechnology Company Ltd. (“**Tianjin JuveStar**”), was released. JS-001 is a product from Israel licensed to Tianjin JuveStar. The phase 2b clinical result of JS-001 (RZL-012) on submental fat reduction has reached the primary endpoint. Sisram Medical is a global consumer wellness group, featuring a unique synergistic ecosystem of business building blocks and consumer-focused branding, ranging from medical aesthetics capital equipment, via injectables therapy, aesthetic dentistry, personal care and more,

Active ingredient of JS-001 is a synthetic small molecule, without any human or animal substance in the formula. Pre-clinical and clinical studies’ data demonstrate that JS-001 can induce adipocyte decay and reduce thickness of fat layer, so that can be used for body contouring.

Regarding the phase IIb study which was recently completed in the US, on the 84<sup>th</sup> day after a single injection with JS-001, the volume of submental fat was reduced by 15% on average. Most adverse events were local and transient.

Figure 1: Submental change after treatment with JS-001





Figure 2: Submental fat change on day 84 (MRI)



In addition, previous phase IIa study with JS-001 on abdominal fat reduction shows, fat volume on injection site was reduced by 15-20%.

According to the *White Book of China Body Contouring Market 2021* published by Deloitte & Allergan Aesthetics, the size of the body contouring market in China is about RMB17.2 billion in 2022, and will reach to RMB100 billion in 2030.

So far, there is no lipolysis injection in the China market (excluding Hong Kong, Macao and Taiwan). A multi-regional clinical trial (including mainland China) will be initiated in late 2022 to further verify the efficacy and safety of JS-001.

### **About Sisram Medical Ltd**

Sisram Medical Ltd (1696.HK) is a global consumer wellness group, featuring a unique synergistic ecosystem of business building blocks and consumer-focused branding, ranging from medical aesthetics capital equipment, via injectables therapy, aesthetic dentistry, personal care and more. The company is majority held by Fosun Pharma, a leading healthcare group in China. Sisram Medical successfully went public on September 19, 2017, as the first Israeli company listed on the Hong Kong Exchange Main Board.

Sisram Medical – Enhancing Quality of Life

<http://www.sisram-medical.com>

For media inquiries, please contact:

Ever Bloom (HK) Communications Consultants Group Limited

Orianna Ou / Yinmei He

+852 3468 8171

[sisrammed.list@everbloom.com.cn](mailto:sisrammed.list@everbloom.com.cn)